Literature DB >> 30697652

Modeling marginal features in studies of recurrent events in the presence of a terminal event.

Per Kragh Andersen1, Jules Angst2, Henrik Ravn3.   

Abstract

We study models for recurrent events with special emphasis on the situation where a terminal event acts as a competing risk for the recurrent events process and where there may be gaps between periods during which subjects are at risk for the recurrent event. We focus on marginal analysis of the expected number of events and show that an Aalen-Johansen type estimator proposed by Cook and Lawless is applicable in this situation. A motivating example deals with psychiatric hospital admissions where we supplement with analyses of the marginal distribution of time to the competing event and the marginal distribution of the time spent in hospital. Pseudo-observations are used for the latter purpose.

Entities:  

Keywords:  Competing risks; Expected number of events; Intensity-based models; Marginal models; Pseudo-observations; Recurrent events

Mesh:

Year:  2019        PMID: 30697652     DOI: 10.1007/s10985-019-09462-4

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  22 in total

1.  Dynamic analysis of multivariate failure time data.

Authors:  Odd O Aalen; Johan Fosen; Harald Weedon-Fekjaer; Ornulf Borgan; Einar Husebye
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

2.  On pseudo-values for regression analysis in competing risks models.

Authors:  Frederik Graw; Thomas A Gerds; Martin Schumacher
Journal:  Lifetime Data Anal       Date:  2008-12-03       Impact factor: 1.588

3.  Decomposition of number of life years lost according to causes of death.

Authors:  P K Andersen
Journal:  Stat Med       Date:  2013-07-09       Impact factor: 2.373

4.  Marginal analysis of recurrent events and a terminating event.

Authors:  R J Cook; J F Lawless
Journal:  Stat Med       Date:  1997-04-30       Impact factor: 2.373

5.  Pseudo-observations for competing risks with covariate dependent censoring.

Authors:  Nadine Binder; Thomas A Gerds; Per Kragh Andersen
Journal:  Lifetime Data Anal       Date:  2013-02-22       Impact factor: 1.588

6.  Recurrence in affective disorder: analyses with frailty models.

Authors:  L V Kessing; E W Olsen; P K Andersen
Journal:  Am J Epidemiol       Date:  1999-03-01       Impact factor: 4.897

7.  Evaluating risk factors associated with severe hypoglycaemia in epidemiology studies-what method should we use?

Authors:  M K Bulsara; C D J Holman; E A Davis; T W Jones
Journal:  Diabet Med       Date:  2004-08       Impact factor: 4.359

8.  Recurrence of bipolar disorders and major depression. A life-long perspective.

Authors:  Jules Angst; Alex Gamma; Robert Sellaro; Philip W Lavori; Heping Zhang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2003-10       Impact factor: 5.270

9.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Authors:  H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

Review 10.  Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved.

Authors:  Jennifer K Rogers; Stuart J Pocock; John J V McMurray; Christopher B Granger; Eric L Michelson; Jan Östergren; Marc A Pfeffer; Scott D Solomon; Karl Swedberg; Salim Yusuf
Journal:  Eur J Heart Fail       Date:  2013-12-18       Impact factor: 15.534

View more
  4 in total

1.  Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease.

Authors:  Michael Szarek; Connie Hess; Manesh R Patel; W Schuyler Jones; Jeffrey S Berger; Iris Baumgartner; Brian Katona; Kenneth W Mahaffey; Lars Norgren; Juuso Blomster; Frank W Rockhold; Judith Hsia; F Gerry R Fowkes; Marc P Bonaca
Journal:  J Am Heart Assoc       Date:  2022-05-27       Impact factor: 6.106

2.  Health Service Utilization Patterns Among Adults With Congenital Heart Disease: A Population-Based Study.

Authors:  Michal Benderly; Jonathan Buber; Ofra Kalter-Leibovici; Leonard Blieden; Alexander Dadashev; Avraham Lorber; Amiram Nir; Sergei Yalonetsky; Gabriel Chodick; Dahlia Weitzman; Ran Balicer; Efrat Mazor Dray; Havi Murad; Yaron Razon; Rafael Hirsch
Journal:  J Am Heart Assoc       Date:  2021-01-12       Impact factor: 5.501

3.  Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone.

Authors:  Scott D Berkowitz; Rupert M Bauersachs; Michael Szarek; Mark R Nehler; E Sebastian Debus; Manesh R Patel; Sonia S Anand; Warren H Capell; Connie N Hess; Judy Hsia; Nicholas J Leeper; David Brasil; Lajos Mátyás; Rafael Diaz; Marianne Brodmann; Eva Muehlhofer; Lloyd P Haskell; Marc P Bonaca
Journal:  J Thromb Haemost       Date:  2022-03-07       Impact factor: 16.036

4.  Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.

Authors:  Michael Szarek; Vera A Bittner; Philip Aylward; Marie Baccara-Dinet; Deepak L Bhatt; Rafael Diaz; Zlatko Fras; Shaun G Goodman; Sigrun Halvorsen; Robert A Harrington; J Wouter Jukema; Patrick M Moriarty; Robert Pordy; Kausik K Ray; Peter Sinnaeve; Sotirios Tsimikas; Robert Vogel; Harvey D White; Doron Zahger; Andreas M Zeiher; Ph Gabriel Steg; Gregory G Schwartz
Journal:  Eur Heart J       Date:  2020-11-21       Impact factor: 29.983

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.